Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies

ConclusionsThis prospective clinical trial provides updated PK data revealing Lipiodol distribution as an imaging marker predictive of DOX-Cmax and tumor response after cTACE in liver cancer.Key Points•Prospective pharmacokinetic analysis after conventional TACE revealed Lipiodol distribution (1 vs.≥ 2 segments vs.lobar) as an imaging marker predictive of doxorubicin peak concentrations (Cmax).•Child-Pugh B class and tumor hypervascularization, measurable as enhancing tumor volume (ETV) at baseline, were identified as additional predictors for higher dose-normalized doxorubicin Cmaxafter conventional TACE.•ETV at baseline and tumoral Lipiodol coverage can serve as predictors of volumetric tumor response after conventional TACE according to quantitative European Association for the Study of the Liver (qEASL) criteria.
Source: European Radiology - Category: Radiology Source Type: research